In order to ensure 2023 billing, testing must be activated before the end of the year, or within 30 days of proband sample collection (if sample was collected in 2023). For Exome, Genome, or Xpanded testing, if you do not expect parental samples to be received in time for testing to be activated with 2023 billing, please contact us at firstname.lastname@example.org to determine how to proceed.
At GeneDx, our goal is to provide clear, accurate, and meaningful answers that healthcare providers, patients, families, and partners can trust. We accomplish this through extensive expertise, cutting-edge research and technology, sound science, and a deep database.
Detection. Discovery. Diagnosis. We are the industry’s genetic testing experts, focused on enhancing patient care through genomic insights.
Using the latest technology, proprietary informatics software, rich internal database, and extensive clinical expertise, we identify difficult-to-detect genetic variation and more accurately assess its contribution to disease to deliver clear, actionable results.
GeneDx has identified and published more than 400 new disease-gene relationships and developed novel tools for genomic data analysis.
Transparent, responsible research drives our understanding of genetic disorders, and collaborations enable the development of novel treatments. If you are a researcher or clinician looking to identify a clinical cohort, the GeneDx research group can facilitate connections.
We are collaborating on a landmark genomic newborn screening study focused on screening 100,000 newborns for 250 genetic conditions with known interventions that can prevent or lessen the symptoms of the condition. Early diagnosis of a genetic condition can guide treatment options, medications, or interventions to prevent or reduce symptoms.
We are collaborating to demonstrate the broad utility of rapid whole genome sequencing for critically ill babies. Results are expected to provide guidance about the best ways to help find a precise genetic diagnosis, better anticipate patient needs, and take advantage of new treatments.
For every new disease-causing gene we publish, GeneDx offers exome sequencing at no cost to a patient who meets clinical criteria and cannot otherwise afford or have access to this testing.